Can M1 Macrophages be Therapeutically Targeted in Cancer?
Yes, targeting M1 macrophages is a promising therapeutic strategy in cancer. One approach is to use agents that promote the polarization of macrophages towards the M1 phenotype. For instance, IFN-γ or toll-like receptor (TLR) agonists can be used to activate M1 macrophages. Another strategy is to inhibit pathways that lead to M2 polarization, thereby tipping the balance in favor of M1 macrophages. Additionally, adoptive transfer of ex vivo-activated M1 macrophages into the TME is being explored as a potential cancer therapy.
